Class III and IV Registration Strategy in Argentina

1. Key takeaways

Class III / IV devices in Argentina can only follow the conventional registration pathway: a complete technical dossier is submitted, ANMAT conducts a full technical review, and upon approval the registration is granted by administrative act and a PM registration number is assigned. No simplified or declaration-based shortcut exists for this risk tier.

Two decision points are critical: where the technical report cannot sufficiently demonstrate the product’s safety and effectiveness, ANMAT will require a clinical study for the product; and ANMAT retains the power to initiate GMP inspections at manufacturing sites, with a higher trigger probability for Class III/IV. The registration strategy for Class III/IV is therefore essentially the superposition of two strategies — evidence preparation and inspection preparation. The official administrative review window is at most about 110 business days, while the practical end-to-end cycle is typically 12–15 months.

Nothing in the framework offers a shortcut for this tier: no declaration route, no notification channel, no reliance mechanism. That is by design, since Class III/IV devices concentrate the implantable, life-supporting and high-energy technologies where failure carries the greatest consequences. The planning question is therefore not how to avoid the full review but how to move through it without avoidable stalls — which reduces, in practice, to the quality of the evidence file and the readiness of the manufacturing site.

2. Legal basis

The instruments below govern the conventional registration procedure, the technical report format, GMP inspections, and the clinical research standards.

3. Expert insights

Insight 1: the trigger for a clinical study is an insufficient technical report, not a fixed class threshold. This differs from markets where Class III automatically means a clinical trial. Argentina’s standard is evidentiary sufficiency: a product with existing CE or FDA approval and adequate supporting clinical literature may pass on a technical report plus a clinical evaluation report; a novel design or a product without sufficient literature support will almost certainly be required to add a clinical study.

Insight 2: the GMP inspection is the largest uncontrollable variable in the Class III/IV cycle. ANMAT retains inspection authority over manufacturing sites, with a higher trigger probability for Class III/IV. Inspection scheduling is outside the applicant’s control, and once triggered, the cycle can extend by several months. Closing GMP gaps in advance is far more efficient than waiting passively for the inspection to arrive.

Insight 3: Disposición 7516/2025 adopting ICH E6 (R3) raises the clinical research baseline. Although it is aimed mainly at clinical pharmacology studies, it brings Argentina’s clinical research standards to the international level. Companies that need to run device clinical studies in Argentina must design and conduct trials to ICH E6 (R3) and cannot rely on older local practice.

Strategy for this tier is best expressed as two parallel workstreams that converge at filing: an evidence workstream that anticipates ANMAT’s sufficiency standard, and a site workstream that anticipates the GMP inspection. Neither can compensate for the other, and the project plan should carry both with named owners and dated milestones. The recommendations below allocate concrete actions to each workstream and tie them to the overall schedule.

4. Practical recommendations

1. Prepare the evidence in layers. Layer one: the technical report (Annex V format) plus the risk management report; layer two: the clinical evaluation report (including equivalence comparison and literature); layer three: the clinical study protocol. Activate each layer in response to ANMAT feedback rather than investing everything up front.
2. Explain the differences for CE/FDA data. When citing foreign clinical data, attach a one-page statement of its applicability under Argentine rules, focusing on population differences and differences in the conditions of use.
3. Close GMP gaps before filing. Run a mock GMP inspection before submission, focusing remediation on facility and equipment maintenance, production process controls, material traceability and training records.
4. Reserve an inspection window in the schedule. Build Class III/IV project plans on the 12–15 month base and add a further buffer for one GMP inspection.

5. Verification checklist

Confirm each item below before filing a Class III/IV application.

• □ The product has been confirmed as Class III/IV and subject to the conventional registration pathway
• □ The technical report has been prepared in the Annex V format of GMC 25/21
• □ The risk management report (ISO 14971) is complete and consistent with the technical report
• □ The clinical evaluation report is ready, with equivalence comparison and literature support
• □ The likelihood of a required clinical study has been assessed and a contingency plan prepared
• □ A mock GMP inspection and gap remediation have been completed at the manufacturing site
• □ The project schedule reserves a buffer window for a GMP inspection

Given the length of the cycle and the number of parallel workstreams, review this checklist at defined milestones — dossier completion, pre-filing, response to each deficiency round, and after any inspection — rather than only once before filing. Each review either confirms readiness for the next step or identifies the next remediation action while there is still time to act.

Regulatory information verified as of October 29, 2026.

In Argentina, GRZAN operates a wholly-owned subsidiary that can act as the registration holder and importer for foreign manufacturers, directly handling classification assessment, pathway selection, GMP and CFS documentation chains, Spanish-language technical documentation and labeling localization, HELENA submissions and deficiency responses, as well as BONITA import notifications, ARGOS vigilance system operation, change maintenance and 5-year renewal planning.

The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience and tracks the developments of regulatory authorities worldwide. All published content follows the drafting standard of conclusions first, traceable legal basis, and verifiable figures. For an Argentina or MERCOSUR market-access plan tailored to a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.